Preview

Экспериментальная и клиническая гастроэнтерология

Расширенный поиск

НАЖБП-ассоциированная коморбидность

https://doi.org/10.31146/1682-8658-ecg-194-10-5-13

Полный текст:

Аннотация

Неалкогольная жировая болезнь печени (НАЖБП) рассматривается не только как заболевание с неблагоприятным печеночным прогнозом. Проблема приобрела мультидисциплинарный характер, а многообразие сопутствующих заболеваний и патологических состояний объединены общими патофизиологическими механизмами.

В данном обзоре обобщены и представлены имеющиеся в современной литературе данные об ассоциации НАЖБП с сердечно-сосудистыми заболеваниями, сахарным диабетом 2 типа, синдромом поликистозных яичников, хронической болезнью почек, и т.д. Обсуждается роль печени в гомеостазе организма и патогенетические механизмы формирования НАЖБП- ассоциированной коморбидности.

Об авторах

Л. Б. Лазебник
Московский государственный медико-стоматологический университет им. А.И. Евдокимова
Россия

Лазебник Леонид Борисович - доктор медицинских наук, профессор кафедры поликлинической терапии, профессор.

ул. Делегатская, 20/1, Москва, 127473.



С. В. Туркина
Волгоградский государственный медицинский университет Министерства здравоохранения РФ
Россия

Туркина Светлана Владимировна – доктор медицинских наук, профессор кафедры внутренних болезней.

400131, Волгоград.



Список литературы

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431. PMID: 26707365.

2. Younossi Z., Anstee Q., Marietti M. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018; 15: 11-20 doi: 10.1038/nrgastro.2017.109.

3. Drapkina O., Evsyutina Y., Ivashkin V. Prevalence of non-alcoholic fatty liver disease in the Russian Federation: the open, multicenter, prospective study, DIREG 1. American Journal of Clinical Medicine Research. 2015; 3 (2): 31-36.

4. Drapkina O. M., Ivashkin V. T. Liver disease structure explored in Russian Federation: national-wide DIREG-L-01903 study for non-alcoholic fatty liver disease screening. Journal of Hepatology. 2011; 54: 332.

5. Ивашкин В. Т., Драпкина О. М., Маев И. В., Трухманов А. С., и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015; 6:31-41.

6. Estes C., Anstee Q. M., Arias-Loste M.T., et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896-904. doi: 10.1016/j.jhep.2018.05.036. PMID: 29886156.

7. Huang D.Q., El-Serag H.B., Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223-238. doi: 10.1038/s41575-020-00381-6.

8. Younossi Z.M., Stepanova M., Ong J., Trimble G., et al. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19(3):580-589.e5. doi: 10.1016/j.cgh.2020.05.064. PMID: 32531342.

9. Kim D., Kim W. R., Kim H. J., Therneau T. M. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57(4):1357-65. doi: 10.1002/hep.26156.

10. Francque S.M., van der Graaff D., Kwanten W. J. Nonalcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425-43. doi: 10.1016/j.jhep.2016.04.005. PMID: 27091791.

11. Zhou Y.Y., Zhou X. D., Wu S. J., Fan D. H., et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. Hepatol Commun. 2018; 2: 376-392. doi: 10.1002/hep4.1155.

12. Tana C., Ballestri S., Ricci., Di Vincenzo A., et al. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health. 2019;16(17):3104. doi: 10.3390/ijerph16173104. PMID: 31455011; PMCID: PMC6747357.

13. Leake I. NAFLD and risk of cardiovascular disease. Nat Rev Gastroenterol Hepatol. 2019; 16: 706. doi: 10.1038/s41575-019-0234-7.

14. Targher G., Byrne C. D., Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691-1705. doi: 10.1136/gutjnl-2020-320622. PMID: 32321858.

15. Kasper P., Martin A., Lang S., Kutting F., et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921-937. doi: 10.1007/s00392-020-01709-7. PMID: 32696080.

16. Przybyszewski E. M., Targher G., Roden M, Corey K. E. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. Clin Liver Dis (Hoboken). 2021 1;17(1):19-22. doi: 10.1002/cld.1017. PMID: 33552481.

17. Francque S. The Liver and the Cardiovascular System: Two of a Kind? J Am Heart Assoc. 2021;10(8): e020286. doi: 10.1161/JAHA.121.020286.

18. Chang Y., Ryu S., Sung E., Woo H. Y., et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008;57:569-576. doi: 10.1016/j.metabol.2007.11.022.

19. Targher G., Chonchol M., Bertolini L., Rodella S., et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564-1570. doi: 10.1681/ASN.2007101155.

20. Lubel J. S., Herath C. B., Burrell L. M., Angus P. W. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J. Gastroenterol. Hepatol. 2008; 23 (9): 1327-38. doi: 10.1111/j.1440-1746.2008.05461.x.

21. Targher G., Bertolini L., Rodella S., Lippi G., et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010;5:2166-2171. doi: 10.2215/CJN.05050610.

22. Park C. W., Tsai N. T., Wong L. L. Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. Clin Transplant. 2011;25(6): E606-11. doi: 10.1111/j.1399-0012.2011.01497.x.

23. Yasui K., Sumida Y., Mori Y., Mitsuyoshi H., et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism. 2011;60:735-739. doi: 10.1016/j.metabol.2010.07.022.

24. Sirota J. C., McFann K., Targher G., Chonchol M., Jalal D. I. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. Am J Nephrol. 2012;36:466-471. doi: 10.1159/000343885.

25. Musso G., Cassader M., Cohney S., et al. Emerging LiverKidney Interactions in Nonalcoholic Fatty Liver Disease. Trends in Molecular Medicine. 2015; 21 (10): 645-662. doi: 10.1016/j.molmed.2015.08.005.

26. Pan L. L., Zhang H. J., Huang Z. F., Sun Q., et al. Intrahepatic triglyceride content is independently associated with chronic kidney disease in obese adults: a cross-sectional study. Metabolism. 2015;64: 1077-1085. doi: 10.1016/j.metabol.2015.06.003.

27. Huh J. H., Kim J. Y., Choi E., Kim J. S., Chang Y., Sung KC. The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. PLoS One. 2017;12: e0180951. doi: 10.1371/journal.pone.0180951.

28. Sinn D. H., Kang D., Jang H. R., Gu S., et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study. J Hepatol. 2017;67:1274-1280. doi: 10.1016/j.jhep.2017.08.024.

29. Jang H. R., Kang D., Sinn D. H., Gu S., et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep. 2018;8:4718. doi: 10.1038/s41598-018-23014-0.

30. Mantovani A., Zaza G., Byrne C. D., Lonardo A., et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism. 2018;79:64-76. doi: 10.1016/j.metabol.2017.11.003.

31. Wilechansky R. M., Pedley A., Massaro J. M., Hoffmann U., et al. Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study. J Intern Med. 2019;286:711-722.

32. Byrne C. D., Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72(4):785-801. doi: 10.1016/j.jhep.2020.01.013. PMID: 32059982.

33. Brown A.., Tendler D. A., McMurray R.G., Setji T. L. Polycystic ovary syndrome and severe nonalcoholic steato-hepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocr Pract. 2005;11(5):319-324. doi: 10.4158/EP.11.5.319.

34. Ramezani-Binabaj M., Motalebi M., Karimi-Sari H., Rezaee-Zavareh M.S., Alavian S. M. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic fatty liver disease; a meta-analysis. Hepat Mon. 2014;14(11): e23235. doi: 10.5812/hepatmon.23235.

35. Targher G., Rossini M., Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine. 2016;51:211-221. doi: 10.1007/s12020-015-0640-8.

36. Chen Hon-Jhe, Yang Hao-Yu, Hsueh Kuang-Chieh, Shen Cheng-Che Chen, et al. Increased risk of osteoporosis in patients with nonalcoholic fatty liver disease. Medicine. 2018; 97 (42): 12835. doi: 10.1097/MD.0000000000012835.

37. Sung J., Ryu S., Song Y. M., Cheong H. K. Relationship Between Non-alcoholic Fatty Liver Disease and Decreased Bone Mineral Density: A Retrospective Cohort Study in Korea. J Prev Med Public Health. 2020;53(5):342-352. doi: 10.3961/jpmph.20.089. PMID: 33070506.

38. Corey K. E., MisdrajiJ., Gelrud L., et al. ObstructiveSleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology. Dig Dis Sci. 2015; 60: 2523-2538. doi: 10.1007/s10620-015-3650-8.

39. Ahn J. S., Sinn D.H, Min Y. W., Hong S. N., et al. Nonalcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Th er. 2017;45(2):345-353. doi: 10.1111/apt.13866. PMID: 27859470.

40. Ganzetti G., Campanati A., Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol. 2015;7(3):315-26. doi: 10.4254/wjh.v7.i3.315. PMID: 25848461.

41. Belinchon-Romero I., Bellot P., Romero-Perez D,. et al. Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients. Sci Rep. 2021; 11: 8593. doi: 10.1038/s41598-021-88043-8

42. Catanzaro R., Calabrese F., Occhipinti S., Anzalone M. G., et al. Nonalcoholic fatty liver disease increases risk for gastroesophageal reflux symptoms. Dig Dis Sci. 2014;59(8):1939-45. doi: 10.1007/s10620-014-3113-7. PMID: 24718860.

43. Fujiwara M., Eguchi Y., Fukumori N., et al. The Symptoms of Gastroesophageal Reflux Disease Correlate with High Body Mass Index, the Aspartate Aminotransferase/ Alanine Aminotransferase Ratio and Insulin Resistance in Japanese Patients with Non-alcoholic Fatty Liver Disease. Intern Med. 2015; 54: 3099-3104. doi: 10.2169/internal-medicine.54.4297.

44. Wijarnpreecha K., Panjawatanan P., Thongprayoon C,. Jaruvongvanich V., Ungprasert P. Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: A meta-analysis. Saudi J Gastroenterol. 2017;23(6):311-317. doi: 10.4103/sjg.SJG_161_17.

45. Xue J., Xin H., Ren N., et al. Nonalcoholic fatty liver disease increases the risk of gastroesophageal reflux disease: A systematic review and meta-analysis. Eur J Clin Invest. 2019; 49 (9): e13158. doi: 10.1111/eci.13158.

46. Buzzetti E., Pinzani M., Tsochatziz E. A. The multiple-hit pathogensesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:103. doi: 10.1016/j.metabol.2015.12.012.

47. Kanwar P., Nelson J. E., Yates K., Kleiner D. E., et al Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterol. 2016;3(1): e000114. doi:10.1136/bm-jgast-2016-000114.

48. Godoy-Matos A.F., Silva Junior W. S. & Valerio, C.M. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020; 12: 60. doi: 10.1186/s13098-020-00570-y.

49. Mitra S., De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020;5:16. doi: 10.21037/tgh.2019.09.08.

50. Caballeria L., Auladell M. A., Toran P., et al. Prevalence and factors associated with the presence of non alcoholic fatty liver disease in an apparently healthy adult population in primary care units. BMC Gastroenterol. 2007;7:41. doi: 10.1186/1471-230X-7-41.

51. Eckel R. H., Grundy S. M., Zimmet P. Z. The metabolic syndrome. Lancet. 2005;365(9468):1415-1428. PMID:15836891.

52. Gastaldelli A., Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019;1:312-328. doi: 10.1016/j.jhepr.2019.07.002.

53. Yang S., Kwak S., Lee J. H., Kang S., Lee S. P. Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population. PLoS One. 2019;14(11): e0224626. doi: 10.1371/journal.pone.0224626.

54. Kumashiro N., Erion D. M., Zhang D., Kahn M, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA. 2011;108(39):16381-5. doi: 10.1073/pnas.1113359108. PMID: 21930939.

55. Meex RCR., Watt M. J. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13(9):509-520. PMID:28621339.

56. Jensen M. K., Bartz T. M., Mukamal K. J., Djousse L., et al. Fetuin-A, type 2 diabetes, and risk of cardiovascular disease in older adults: the cardiovascular health study. Diabetes Care. 2013;36(5):1222-8. doi: 10.2337/dc12-1591.

57. Verras C. G., Christou G. A., Simos Y. V., et al. Serum fetu-in-A levels are associated with serum triglycerides before and 6 months after bariatric surgery. Hormones (Athens Greece). 2017; 16: 297-305. doi: 10.14310/horm.2002.1739.

58. Nascimbeni F., Romagnoli D., Ballestri S., Baldelli E., et al. Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease? Diseases. 2018;6(1):17. doi: 10.3390/diseases 6010017. PMID: 29462898.

59. Pan X., Kaminga A. C., Chen J., Luo M., Luo J. Fetuin-A and Fetuin-B in Non-Alcoholic Fatty Liver Disease: A MetaAnalysis and Meta-Regression. Int J Environ Res Public Health. 2020;17(8):2735. doi: 10.3390/ijerph17082735. PMID: 32326594.

60. Pan X., Wen S. W., Bestman P. L., Kaminga A. C., Acheampong K., Liu A. Fetuin-A in Metabolic syndrome: A systematic review and meta-analysis. PLoS One. 2020;15(3): e0229776. doi: 10.1371/journal.pone.0229776. PMID: 32134969.

61. Kahraman A., Schlattjan M., Pronadl M., Wree A., et al. Reduction of fetuin-A in morbidly obese patients with NAFLD following weight loss by bariatric surgery. Hepatology. 2012; 56: 882A.

62. Zhou Z., Sun M., Jin H., Chen H., Ju H. Fetuin-a to adi-ponectin ratio is a sensitive indicator for evaluating metabolic syndrome in the elderly. Lipids Health Dis. 2020; 19: 61. doi: 10.1186/s12944-020-01251-5.

63. Celebi G., Genc H., Gurel H., Sertoglu, E., et al. The Relationship of circulating Fetuin-A with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease. Saudi J. Gastroenterol. 2015; 21:139-145. doi: 10.4103/13193767.157556.

64. Gehrke N., Schattenberg J. M. Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease? Gastroenterology. 2020;158(7):1929-1947.e6. doi: 10.1053/j.gastro.2020.02.020. PMID: 32068022.

65. Albillos A., de Gottardi A., Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72(3):558-577.doi: 10.1016/j.jhep.2019.10.003. PMID: 31622696.

66. Leech B., McIntyre E., Steel A., Sibbritt D. Risk factors associated with intestinal permeability in an adult population: A systematic review. Int J Clin Pract. 2019;73(10): e13385. doi: 10.1111/ijcp.13385. PMID: 31243854.

67. Tripathi A., Debelius J., Brenner D. A., Karin M., et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15(7):397-411. doi: 10.1038/s41575-018-0011-z. Erratum in: Nat Rev Gastroenterol Hepatol. 2018; PMID: 29748586.

68. De Munck T. J.I., Xu P., Verwijs H. J.A., et al. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis. Liver Int. 2020;40:2906-2916. doi: 10.1111/liv.14696

69. Carpino G., Del Ben M., Pastori D., Carnevale R., et al. Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. Hepatology. 2020;72:470-485. doi: 10.1002/hep.31056.

70. Baratta F., Pastori D., Bartimoccia S., Cammisotto V., et al. Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide Are Associated With Oxidative Stress in Patients With Non-Alcoholic Fatty Liver Disease. Nutrients. 2020;12:17232. doi: 10.3390/nu12061732.

71. Carnevale R., Nocella C., Petrozza V., Cammisotto V., et al. Localization of Lipopolysaccharide from Escherichia Coli into Human Atherosclerotic Plaque. Sci. Rep. 2018;8:1-8. doi: 10.1038/s41598-018-22076-4.

72. Pastori D., Carnevale R., Nocella C., Novo M., et al. Gut-Derived Serum Lipopolysaccharide Is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet. J. Am. Hear. Assoc. 2017;6: e005784. doi: 10.1161/JAHA.117.005784.

73. Carnevale R., Pastori D., Nocella C., Cammisotto V., et al. Gut-Derived Lipopolysaccharides Increase Post-Prandial Oxidative Stress via Nox2 Activation in Patients With Impaired Fasting Glucose Tolerance: Effect of Extra-Virgin Olive Oil. Eur. J. Nutr. 2018;58:843-851. doi: 10.1007/s00394-018-1718-x.

74. Miele L., Valenza V., La Torre G., Montalto M., et al. Increased Intestinal Permeability and Tight Junction Alterations in Nonalcoholic Fatty Liver Disease. Hepatology. 2009;49:1877-1887. doi: 10.1002/hep.2284.

75. KessokuT., Kobayashi T., Tanaka K., Yamamoto A., et al. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int. J. Mol. Sci. 2021; 22,: 8161. doi: 10.3390/ijms22158161.

76. Bakhshimoghaddam F., Alizadeh M. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. Clin Nutr ESPEN. 2021;44:61-68. doi: 10.1016/j.clnesp.2021.05.012. PMID: 34330514.

77. Luther J., Garber JJ., Khalili H., Dave M., et al. Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability. Cell Mol Gastroenterol Hepatol. 2015;1(2):222-232. doi: 10.1016/j.jcmgh.2015.01.001. PMID: 26405687.

78. Stenman L.K., Holma R., Korpela R. High-Fat-Induced Intestinal Permeability Dysfunction Associated With Altered Fecal Bile Acids. World J. Gastroenterol. 2012;18:923-929. doi: 10.3748/wjg.v18.i9.923.

79. de Aguiar Vallim T. Q., Tarling E. J., Edwards P. A. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013;17:657-669. doi: 10.1016/j.cmet.2013.03.013.

80. Sarenac T.M., Mikov M. Bile Acid Synthesis: From Nature to the Chemical Modification and Synthesis and Their Applications as Drugs and Nutrients. Front. Pharm. 2018;9:939. doi: 10.3389/fphar.2018.00939.

81. Kim H., Fang S. Crosstalk between FXR and TGR5 controls glucagon-like peptide 1 secretion to maintain glycemic homeostasis. Lab. Anim. Res. 2018;34:140-146. doi: 10.5625/lar.2018.34.4.140.

82. Iracheta-Vellve A., Calenda C. D., Petrasek J., Ambade A., et al. FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice. Hepatol. Commun. 2018;2:1379-1391. doi: 10.1002/hep4.1256.

83. Chiang J.Y., Pathak P., Liu H., Donepudi A., Ferrell J., Boehme S. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation. Dig. Dis. 2017;35:241-245. doi: 10.1159/000450981.

84. Chiang J.Y.L., Ferrell J. M. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am. J. Physiol. Gastrointest. Liver Physiol. 2020;318: G554-G573. doi: 10.1152/ajpgi.00223.2019.

85. Ridlon J.M., Harris S. C., Bhowmik S., Kang D. J., Hylemon P. B. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016;7:22-39. doi: 10.1080/19490976.2015.1127483.

86. Wang W., Zhao J., Gui W., Sun D., et al. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol. 2018; 175:469-84. doi: 10.1111/bph.14095.

87. Лазебник Л. Б., Голованова Е. В., Туркина С. В., Райхельсон К. Л., Оковитый С. В., Драпкина О. М., Маев И. В., Мартынов А. И., и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;185(1): 4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52.


Рецензия

Для цитирования:


Лазебник Л.Б., Туркина С.В. НАЖБП-ассоциированная коморбидность. Экспериментальная и клиническая гастроэнтерология. 2021;(10):5-13. https://doi.org/10.31146/1682-8658-ecg-194-10-5-13

For citation:


Lazebnik L.B., Turkina S.V. NAFLD Associated Comorbidity. Experimental and Clinical Gastroenterology. 2021;(10):5-13. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-194-10-5-13

Просмотров: 57


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)